October 22, 2016 10:11 PM ET

Healthcare Equipment and Supplies

Company Overview of Infraredx, Inc.

Company Overview

Infraredx, Inc. operates as a cardiovascular imaging medical device company. It offers diagnosis and treatment of coronary artery diseases. The company’s products include dual-modality near-infrared spectroscopy intravascular ultrasound (IVUS) true vessel characterization imaging systems for identifying lipid core coronary plaques, and providing structural plaque information with IVUS; and optical catheters that provides a high resolution image of the structure of the plaque, as well as associated accessories. It serves hospital sites in the United States and Europe. The company was formerly known as InfraReDx, Inc. and changed its name to Infraredx, Inc. in November, 2012. Infraredx, Inc. w...

34 Third Avenue

Burlington, MA 01803

United States

Founded in 1998

130 Employees





Key Executives for Infraredx, Inc.

Chief Executive Officer, President and Director
Age: 44
Chief Financial Officer
Senior Vice President of Technology Innovation
Age: 50
Vice President of Product Development
Vice President of Research
Compensation as of Fiscal Year 2016.

Infraredx, Inc. Key Developments

InfraReDx Seeks Acquisitions

InfraReDx, Inc. has filed an IPO in the amount of $55 million. InfraReDx said, "We may use a portion of our net proceeds to acquire and invest in complementary products, technologies or businesses; however, we currently have no agreements or commitments to complete any such transaction and are not involved in negotiations to do so."

Infraredx Announces Research Collaboration with Massachusetts General Hospital to Explore New Generation of Cardiovascular Imaging Devices

Infraredx, Inc. announced a collaboration with Massachusetts General Hospital (MGH) and coronary imaging researcher, Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar, and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The TVC Imaging System is the only FDA-cleared technology capable of rapidly, specifically and reliably identifying lipid core plaques, which are known to complicate stenting procedures and are suspected to be the vulnerable plaques that cause most heart attacks, using NIRS, and providing vessel structure information using intravascular ultrasound (IVUS). The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Infraredx, Inc., please visit www.infraredx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.